Receiving a high dose of Priovant Therapeutics’ oral treatment candidate brepocitinib in a clinical trial led to substantial reductions in symptom severity for all participants with cutaneous sarcoidosis, in which the disease affects the skin, new data show. Further, no serious side effects were reported in the…